Abstract
Summary
CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE), X-linked genetic condition which results in early-onset, difficult to control seizures and severe neuro-developmental impairment. CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were first identified as disease-causing in 2004. CDD was previously not considered as a separate indication; rather, it was assumed to be an atypical form of Rett Syndrome. The CDKL5 gene provides instructions for making proteins that are essential for normal brain and neuron development. The condition was previously known as serine/threonine-protein kinase 9 (STK9), and it has been classified as DEE because the genetic change causes epileptic activity as well as severe impairment of the development. The CDKL5 gene is located on the X chromosome. The X chromosome is one of the sex chromosomes; females have two X’s, and males have one X and one Y chromosome. Although many identified patients are males, because of the location of the gene, this disorder mainly affects females. Affected males may have more severe symptoms than females.
The global market for CDKL5 Deficiency Disorder (CDD) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for CDKL5 Deficiency Disorder (CDD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CDKL5 Deficiency Disorder (CDD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for CDKL5 Deficiency Disorder (CDD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of CDKL5 Deficiency Disorder (CDD) include Marinus Pharmaceuticals, Ovid Therapeutics/Takeda, Zogenix and PTC Therapeutics, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CDKL5 Deficiency Disorder (CDD), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CDKL5 Deficiency Disorder (CDD) by region & country, by Type, and by Application.
The CDKL5 Deficiency Disorder (CDD) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CDKL5 Deficiency Disorder (CDD).
Market Segmentation
By Company
Marinus Pharmaceuticals
Ovid Therapeutics/Takeda
Zogenix
PTC Therapeutics
Segment by Type:
Traditional Drugs
Emerging Drugs
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CDKL5 Deficiency Disorder (CDD) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CDKL5 Deficiency Disorder (CDD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CDKL5 Deficiency Disorder (CDD) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for CDKL5 Deficiency Disorder (CDD) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for CDKL5 Deficiency Disorder (CDD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CDKL5 Deficiency Disorder (CDD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for CDKL5 Deficiency Disorder (CDD) was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of CDKL5 Deficiency Disorder (CDD) include Marinus Pharmaceuticals, Ovid Therapeutics/Takeda, Zogenix and PTC Therapeutics, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CDKL5 Deficiency Disorder (CDD), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CDKL5 Deficiency Disorder (CDD) by region & country, by Type, and by Application.
The CDKL5 Deficiency Disorder (CDD) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CDKL5 Deficiency Disorder (CDD).
Market Segmentation
By Company
Marinus Pharmaceuticals
Ovid Therapeutics/Takeda
Zogenix
PTC Therapeutics
Segment by Type:
Traditional Drugs
Emerging Drugs
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CDKL5 Deficiency Disorder (CDD) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CDKL5 Deficiency Disorder (CDD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CDKL5 Deficiency Disorder (CDD) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 CDKL5 Deficiency Disorder (CDD) Product Introduction
1.2 Global CDKL5 Deficiency Disorder (CDD) Market Size Forecast
1.3 CDKL5 Deficiency Disorder (CDD) Market Trends & Drivers
1.3.1 CDKL5 Deficiency Disorder (CDD) Industry Trends
1.3.2 CDKL5 Deficiency Disorder (CDD) Market Drivers & Opportunity
1.3.3 CDKL5 Deficiency Disorder (CDD) Market Challenges
1.3.4 CDKL5 Deficiency Disorder (CDD) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global CDKL5 Deficiency Disorder (CDD) Players Revenue Ranking (2023)
2.2 Global CDKL5 Deficiency Disorder (CDD) Revenue by Company (2019-2024)
2.3 Key Companies CDKL5 Deficiency Disorder (CDD) Manufacturing Base Distribution and Headquarters
2.4 Key Companies CDKL5 Deficiency Disorder (CDD) Product Offered
2.5 Key Companies Time to Begin Mass Production of CDKL5 Deficiency Disorder (CDD)
2.6 CDKL5 Deficiency Disorder (CDD) Market Competitive Analysis
2.6.1 CDKL5 Deficiency Disorder (CDD) Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by CDKL5 Deficiency Disorder (CDD) Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CDKL5 Deficiency Disorder (CDD) as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Traditional Drugs
3.1.2 Emerging Drugs
3.2 Global CDKL5 Deficiency Disorder (CDD) Sales Value by Type
3.2.1 Global CDKL5 Deficiency Disorder (CDD) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global CDKL5 Deficiency Disorder (CDD) Sales Value, by Type (2019-2030)
3.2.3 Global CDKL5 Deficiency Disorder (CDD) Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global CDKL5 Deficiency Disorder (CDD) Sales Value by Application
4.2.1 Global CDKL5 Deficiency Disorder (CDD) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global CDKL5 Deficiency Disorder (CDD) Sales Value, by Application (2019-2030)
4.2.3 Global CDKL5 Deficiency Disorder (CDD) Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global CDKL5 Deficiency Disorder (CDD) Sales Value by Region
5.1.1 Global CDKL5 Deficiency Disorder (CDD) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global CDKL5 Deficiency Disorder (CDD) Sales Value by Region (2019-2024)
5.1.3 Global CDKL5 Deficiency Disorder (CDD) Sales Value by Region (2025-2030)
5.1.4 Global CDKL5 Deficiency Disorder (CDD) Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
5.2.2 North America CDKL5 Deficiency Disorder (CDD) Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
5.3.2 Europe CDKL5 Deficiency Disorder (CDD) Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
5.4.2 Asia Pacific CDKL5 Deficiency Disorder (CDD) Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
5.5.2 South America CDKL5 Deficiency Disorder (CDD) Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
5.6.2 Middle East & Africa CDKL5 Deficiency Disorder (CDD) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions CDKL5 Deficiency Disorder (CDD) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions CDKL5 Deficiency Disorder (CDD) Sales Value
6.3 United States
6.3.1 United States CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
6.3.2 United States CDKL5 Deficiency Disorder (CDD) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States CDKL5 Deficiency Disorder (CDD) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
6.4.2 Europe CDKL5 Deficiency Disorder (CDD) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe CDKL5 Deficiency Disorder (CDD) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
6.5.2 China CDKL5 Deficiency Disorder (CDD) Sales Value by Type (%), 2023 VS 2030
6.5.3 China CDKL5 Deficiency Disorder (CDD) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
6.6.2 Japan CDKL5 Deficiency Disorder (CDD) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan CDKL5 Deficiency Disorder (CDD) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
6.7.2 South Korea CDKL5 Deficiency Disorder (CDD) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea CDKL5 Deficiency Disorder (CDD) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
6.8.2 Southeast Asia CDKL5 Deficiency Disorder (CDD) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia CDKL5 Deficiency Disorder (CDD) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India CDKL5 Deficiency Disorder (CDD) Sales Value, 2019-2030
6.9.2 India CDKL5 Deficiency Disorder (CDD) Sales Value by Type (%), 2023 VS 2030
6.9.3 India CDKL5 Deficiency Disorder (CDD) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Marinus Pharmaceuticals
7.1.1 Marinus Pharmaceuticals Profile
7.1.2 Marinus Pharmaceuticals Main Business
7.1.3 Marinus Pharmaceuticals CDKL5 Deficiency Disorder (CDD) Products, Services and Solutions
7.1.4 Marinus Pharmaceuticals CDKL5 Deficiency Disorder (CDD) Revenue (US$ Million) & (2019-2024)
7.1.5 Marinus Pharmaceuticals Recent Developments
7.2 Ovid Therapeutics/Takeda
7.2.1 Ovid Therapeutics/Takeda Profile
7.2.2 Ovid Therapeutics/Takeda Main Business
7.2.3 Ovid Therapeutics/Takeda CDKL5 Deficiency Disorder (CDD) Products, Services and Solutions
7.2.4 Ovid Therapeutics/Takeda CDKL5 Deficiency Disorder (CDD) Revenue (US$ Million) & (2019-2024)
7.2.5 Ovid Therapeutics/Takeda Recent Developments
7.3 Zogenix
7.3.1 Zogenix Profile
7.3.2 Zogenix Main Business
7.3.3 Zogenix CDKL5 Deficiency Disorder (CDD) Products, Services and Solutions
7.3.4 Zogenix CDKL5 Deficiency Disorder (CDD) Revenue (US$ Million) & (2019-2024)
7.3.5 PTC Therapeutics Recent Developments
7.4 PTC Therapeutics
7.4.1 PTC Therapeutics Profile
7.4.2 PTC Therapeutics Main Business
7.4.3 PTC Therapeutics CDKL5 Deficiency Disorder (CDD) Products, Services and Solutions
7.4.4 PTC Therapeutics CDKL5 Deficiency Disorder (CDD) Revenue (US$ Million) & (2019-2024)
7.4.5 PTC Therapeutics Recent Developments
8 Industry Chain Analysis
8.1 CDKL5 Deficiency Disorder (CDD) Industrial Chain
8.2 CDKL5 Deficiency Disorder (CDD) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 CDKL5 Deficiency Disorder (CDD) Sales Model
8.5.2 Sales Channel
8.5.3 CDKL5 Deficiency Disorder (CDD) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer